MTE #7: What to Do With Hepatocellular Carcinoma Screening and Surveillance in Patients With Prior Hepatitis C Virus Infection (Ticketed)

Nov 06 2026

Convention Center: Room 4A

7:00 AM - 7:45 AM

Ticketed Event

CE Credits

World Class Speakers

Maria Buti

Discussion Leader

Kali Zhou

Discussion Leader

Description

Join experts to discuss advances in hepatocellular carcinoma (HCC) management among persons with current or prior hepatitis C virus (HCV) infection. Presenters highlight updated American Association for the Study of Liver Diseases guidelines including the optimal timing of HCV treatment and post sustained virologic response (SVR) HCC surveillance. Other topics include the epidemiology of HCC in persons with chronic or prior HCV infection, and whether fibrosis regression following SVR affects HCC screening or surveillance interverals.

Objectives

Review the epidemiology of hepatocellular carcinoma (HCC) in persons with chronic or prior HCV infection.
Identify populations who need long-term HCC screening after achieving a sustained virologic response (SVR) to HCV antiviral therapy.
Discuss whether fibrosis regression following SVR impacts screening intervals for persons without prior HCC or surveillance intervals for persons with prior HCC.